Soluble receptor for advanced glycation endproducts (sRAGE) as a new biomarker of asthma in children: a brief review of the literature and our own findings

Abstract

In recent years, the receptor of glycosylation end products (RAGE) has increasingly attracted the attention of researchers and plays an important role in various in various diseases associated with tissue destruction, metabolic and neurodegenerative processes, infections, immune reactions and inflammation of various origins. The study of the soluble form of this receptor (sRAGE) as a potential biomarker for the diagnosis and monitoring of bronchial asthma (BA) in children is becoming particularly relevant. This article presents a brief review of the literature on the role of RAGE and its ligands in the pathogenesis of respiratory diseases, and analyzes our own data on the study of sRAGE levels in children with AD. We examined 101 children aged 7-18 years suffering from AD referred to the Children’s Allergy Center (Krasnoyarsk, Russia). Children with AD were divided into three groups: controlled (n = 45), partially controlled (n = 19) and uncontrolled asthma (n = 37) according to GINA-2023. The control group consisted of 92 age- and sex-matched children (virtually healthy children without signs of infection or allergy). Serum sRAGE levels were determined by magnetic immunoassay (MAGPIX, Luminex, USA; Merk Millipore, USA). Data are presented as median (25-75% quartiles). The Kruskal–Wallis test was used. Serum sRAGE levels were reduced only in uncontrolled AD in the examined children (Figure 1, p (Kruskal–Wallis test) = 0.001). In addition, serum sRAGE levels were reduced in the asthma exacerbation groups, regardless of exacerbation status caused by viral infection or allergens. Thus, serum sRAGE levels are closely related to asthma control and exacerbation status in children with AD in and may be used as a novel marker of loss of disease control and possibly as a potential target for therapeutic intervention.